CD49b, a Major Marker of Regulatory T-Cells Type 1, Predicts the Response to Antiviral Therapy of Recurrent Hepatitis C after Liver Transplantation

Table 3

Characteristics of responder and nonresponder groups at 18 months.

Characteristics	Responder; (PCR < 0); 𝑁=16	Nonresponder; (PCR > 0); 𝑁=11	𝑃
% of patients	62%	38%
Age (years)	54±13	57±7	0.53
Weight (kg)	74.7±12.7	80.3±14.3	0.39
HCV genotype	Gen 1: 𝑛 = 10 (62%); Gen 2: 𝑛 = 1 (6.5%); Gen 3: 𝑛 = 4 (25%); Gen 4: 𝑛 = 1 (6.5%)	Gen 1: 𝑛 = 8 (73%); Gen 2: 𝑛 = 0; Gen 3: 𝑛 = 1 (9%); Gen 4: 𝑛 = 2 (18%)
Basal Creatinine (µmol/L)	21.8±24.9	103.3±39.9	0.26
Cyclosporin/Tacrolimus	6 (46%)/7 (54%)	3 (38%)/5 (62%)
Use of EPO	All patients	All patients
Viral load (log)	6.22 ± 0.59	6.75 ± 0.42	0.54
METAVIR score (𝑛)	𝐹1 (10); 𝐹2 (5); 𝐹3 (1); 𝐹4 (0)	𝐹1 (5); 𝐹2 (3); 𝐹3 (2); 𝐹4 (1)
Donnor age > 40	53%	58%	NS